Mithra Signs LSA for Commercialization of Estelle® in North Africa

  • Mithra grants exclusive license to GyneBio Pharma for commercialization of its combined oral contraceptive Estelle® in Algeria, Morocco and Tunisia
  • Deal worth up to EUR 25 million for Mithra over the contract period
  • Agreement follows licensing deals for Estelle® with market leaders in key regions such as U.S., Europe, Australia, South America, ASEAN and Middle East

Liege, Belgium, 19 October 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and supply agreement with Gynebio Pharma for the commercialization of Estelle® in North Africa. Estelle® is a novel, next generation oral contraceptive product candidate containing Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg, with a unique benefit/risk profile.